공고 • Mar 31
CRISM Therapeutics Corporation Provides Positive Update Regarding Its Clinical Trial Authorisation Application CRISM Therapeutics Corporation provided a positive update regarding its clinical trial authorisation application to evaluate irinotecan ChemoSeed in patients with high grade glioma. CRISM has been working with the Medicines and Healthcare products Regulatory Agency to finalise the design of the first in-human trial of ChemoSeed and is pleased to confirm it has received positive written scientific advice from the MHRA on the development, clinical trial programme and potential Market Authorisation Application for the commercialisation of ChemoSeed. The written advice confirms that further preclinical toxicology studies will not be required, which will significantly reduce the cost and time of the development work. The Company had previously estimated a cost of approximately PS400,000 to conduct the toxicology studies. In addition, the MHRA agreed that there is a biological basis supporting the benefits of ChemoSeed and that more drugs and methods of delivery are needed for this disease. MHRA was supportive of CRISM's novel dose escalation study for ChemoSeed, confirming that the trial design was appropriate for a Phase 2 clinical trial. The MHRA provided recommendations to improve aspects of the clinical trial to make it more suited to achieving potential market authorisation. The Company is now progressing these recommendations, with support and advice from its contract research organisation, Aixial, and its medical advisers. The Company expects to finalise its CTA application for submission in first quarter 2025 and to begin clinical trials of ChemoSeed in fourth quarter 2025, subject to MHRA and other external regulatory organizations meeting expected review times. The Company has also appointed Ryan LLC, which has a specialisation in accessing grant funding, to assist CRISM secure grant funding specifically for this clinical trial. Ryan has an excellent track record in achieving successful grant applications and has already identified opportunities for which ChemoSeed is likely to qualify. 공고 • Mar 28
CRISM Therapeutics Corporation Announces Grant Awarded by Innovate UK CRISM Therapeutics Corporation announced that it has been awarded a grant by Innovate UK to support the pre-clinical development of the Company's proprietary ChemoSeed technology in prostate cancer (the "Project"). The Project is in line with the Company's strategy as detailed in the admission document published when CRISM joined the Aim market last year and which highlighted the potential of ChemoSeed in multiple disease areas. The Innovate UK grant was awarded as part of the Government's 'Launchpad: life and health sciences, Northern Ireland - Rd2 MFA'. Under the terms of the grant, CRISM will develop a docetaxel-loaded implantable drug delivery technology ("docetaxel ChemoSeed") for intraprostatic chemotherapy, addressing the critical need for localised, effective, and less toxic prostate cancer treatment. Docetaxel ChemoSeed is differentiated from other approaches in that it is implanted inside the prostate, overcoming the non-lipophilic characteristics of the prostate which prevent traditional chemotherapy from having a therapeutic effect. The Project, which will take about 12 months, is designed to deliver: A functional prototype of the implantable device; Pre-clinical validation data demonstrating safety and efficacy; IP protection through patents for core innovations; Scalable manufacturing protocols for commercialisation. The outputs from the Project will establish a foundation for the design of clinical trials, the regulatory approval pathway and market introduction, addressing a critical unmet medical need in prostate cancer therapy. The total cost of the Project is £152,550, and covers key areas such as staffing, overheads, subcontracting, preclinical validation, and regulatory and IP advice. The Company is receiving a grant of £96,106, which represents 63% of the total cost. The remaining £56,444 will be funded through contributions from CRISM. The Project will be carried out in partnership with Ulster University, Queen's University Belfast and Axis Bio, a preclinical contract research organisation, which will complete the preclinical validation to assess the efficacy and safety of the docetaxel ChemoSeed. 공고 • Sep 09
CRISM Therapeutics Corporation to Report First Half, 2024 Results on Sep 19, 2024 CRISM Therapeutics Corporation announced that they will report first half, 2024 results on Sep 19, 2024 공고 • May 15
Amur Minerals Corporation, Annual General Meeting, May 29, 2024 Amur Minerals Corporation, Annual General Meeting, May 29, 2024. Location: the offices of fieldfisher llp, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom 공고 • Nov 13
Amur Minerals Corporation, Annual General Meeting, Nov 30, 2023 Amur Minerals Corporation, Annual General Meeting, Nov 30, 2023, at 10:00 Coordinated Universal Time. Location: offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane London United Kingdom 공고 • Sep 25
Amur Minerals Corporation Announces Special Dividend Amur Minerals Corporation announced to pay a one-time special dividend of 1.8 pence per ordinary share within 90 days of receipt of the completion payment. 
